Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Naive CHB Patients in China (EVOLVE)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01726439
First received: November 6, 2012
Last updated: June 23, 2014
Last verified: June 2014
  Purpose

To compare the effectiveness, in a real world practice setting in tier 2 cities of China, of Entecavir (ETV) monotherapy and Lamivudine (LAM) based therapies (including LAM monotherapy, de novo LAM + Adefovir [ADV] combination, and early add-on of ADV) among chronic hepatitis B (CHB) patients who are naive to NUC at enrollment to this study


Condition
Chronic Hepatitis B

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A 2-year Prospective and Observational Study to Evaluate the Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Chronic Hepatitis B (CHB) Patients Naive to NUC in Real World Practice at Hospitals in Tier 2 Cities in China (the Evolve Study)

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Proportion of patients who achieve virology response (defined as HBV DNA < 300 copies/mL) by ETV monotherapy in comparison with LAM-based therapy [ Time Frame: 48 weeks after initial NUC antiviral therapy ] [ Designated as safety issue: No ]
    Virology response is defined as Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) < 300 copies/mL by a highly sensitive assay such as Roche COBAS or Abbott Real Time Polymerase chain reaction (PCR) performed in a one central laboratory


Secondary Outcome Measures:
  • Mean HBV DNA reductions after 48 weeks of treatment from baseline for ETV and LAM-based therapy patients (stratifying by the 3 LAM-based subgroups) [ Time Frame: Baseline (Day 1) and 48 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients who achieve virology response by ETV in comparison with LAM-based therapy after 24 and 96 weeks of treatment (stratifying by the 3 LAM based subgroups) [ Time Frame: 24 weeks and 96 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients who modify their initial treatment options to manage suboptimal response or resistance after 24, 48, and 96 weeks of treatment among all treatment options [ Time Frame: 24 weeks, 48 weeks and 96 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients who achieve virology response among other treatment options, including ADV, LdT, and combinations of NUCs, after 24, 48 and 96 weeks of treatment [ Time Frame: 24 weeks, 48 weeks and 96 weeks ] [ Designated as safety issue: No ]
    HBV DNA levels at week 24 will be analyzed at the laboratories of hospitals where the patients are treated while evaluation of HBV DNA levels after 48 and 96 weeks of treatment will be conducted at the central laboratory

  • Cumulative incidence of patients who develop viral breakthrough and/or genotypic resistance [ Time Frame: 48 weeks and 96 weeks ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Serum


Estimated Enrollment: 3435
Study Start Date: December 2012
Estimated Study Completion Date: April 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts
CHB patients who are naive to NUC treatment
CHB patients who are naive to NUC at enrollment and be treated at hospitals at tier 2 cities in China

Detailed Description:

Sampling Method: Consecutive patient sampling

Biospecimen Retention: Blood samples for HBV viral load testing along the treatment period of this study

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Hospitals in Chinese tier 2 cities. The definition of these hospitals is the following:

  • Hospitals where 300 or more CHB patients are treated monthly
  • Hospitals where PCR can be performed in the hospital's laboratory to measure HBV DNA serum levels
Criteria

Inclusion Criteria:

  • CHB patients, or CHB patients with compensated cirrhosis, as defined by the current Chinese guidelines
  • Male or female
  • ≥ 18 years of age
  • Either Hepatitis B e antigen (HBeAg) positive or negative
  • Naïve to NUC (defined as no previous exposure to NUC treatment as based on patient self-report)
  • Has compensated liver disease
  • Patients with compensated cirrhosis
  • Patients who consent to participate in this study
  • Local residents with medical reimbursement coverage preferred

Exclusion Criteria:

  • Co-infected with hepatitis C virus (HCV)
  • CHB patients with decompensated cirrhosis, liver failure, hepatocellular carcinoma, or any other types of malignancy at the screening phase
  • CHB patients who are being treated by interferon therapy within 6 months immediately prior to the screening phase of this study
  • CHB patients with a confirmed pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01726439

  Hide Study Locations
Locations
China, Beijing
Local Institution
Beijing, Beijing, China, 100050
China, Chongqing
Local Institution
Chongqing, Chongqing, China, 400038
Local Institution
Chongqing, Chongqing, China, 710032
China, Fujian
Local Institution
Fuzhou, Fujian, China, 350000
Local Institution
Quanzhou, Fujian, China, 362002
Local Institution
Xiamen, Fujian, China, 1361009
China, Guangdong
Local Institution
Foshan, Guangdong, China, 528000
Local Institution
Shenzhen, Guangdong, China, 528000
China, Guangxi
Local Institution
Nanning, Guangxi, China, 530000
China, Guizhou
Local institution
Guiyang, Guizhou, China, 550000
Local Institution
Guiyang, Guizhou, China, 55000
China, Hainan
Local Institution
Haikou, Hainan, China, 570100
China, Hebei
Local Institution
Baoding, Hebei, China, 071000
Local Institution
Shijiazhuang, Hebei, China, 050000
China, Heilongjiang
Local Institution
Daqing, Heilongjiang, China, 163461
Local Institution
Haerbin, Heilongjiang, China, 150086
China, Henan
Local Institution
Zhengzhou, Henan, China, 430000
Local Institution
Zhengzhou, Henan, China, 450000
China, Hubei
Local Institution
Shiyan, Hubei, China, 430000
Local Institution
Wuhan, Hubei, China, 430032
Local Institution
Wuhan, Hubei, China, 430022
China, Hunan
Local Institution
Changsha, Hunan, China, 410008
Local Institution
Changsha, Hunan, China, 410013
Local Institution
Changsha, Hunan, China, 410006
China, Inner Mongolia
Local Institution
Erdos, Inner Mongolia, China, 17000
China, Jiangsu
Local Institution
Changshu, Jiangsu, China, 215500
Local Institution
Changzhou, Jiangsu, China, 213001
Local Institution
Nanjing, Jiangsu, China, 210000
Local Institution
Suzhou, Jiangsu, China, 215000
China, Jiangxi
Local Institution
Nangchang, Jiangxi, China, 330006
China, Jilin
Local Institution
Changchun, Jilin, China, 130000
Local institution
Yanji, Jilin, China, 133000
China, Liaoning
Local Institution
Dalian, Liaoning, China, 116001
Local Instution
Fushun, Liaoning, China, 113000
Local Institution
Shengyang, Liaoning, China
Local Institution
Shenyang, Liaoning, China, 110006
China, Ningxia
Local Institution
Yinchuan, Ningxia, China, 750000
China, Shandong
Local Institution
Jinan, Shandong, China, 250000
Local Institution
Qingdao, Shandong, China, 266000
Local Institution
Yantai, Shandong, China, 264001
China, Shanxi
Local Institution
Taiyuan, Shanxi, China, 30000
Local Institution
Taiyuan, Shanxi, China, 030000
Local Institution
Xi'an, Shanxi, China, 710061
Local Institution
Xi'an, Shanxi, China, 710032
China, Sichuan
Local Institution
Chengdu, Sichuan, China, 610072
Local Institution
Chengdu, Sichuan, China, 610041
China, Tianjin
Local Institution
Tianjin, Tianjin, China, 300000
China, Xinjiang
Local Institution
Urumqi, Xinjiang, China, 830001
Local Institution
Wulumuqi, Xinjiang, China, 830052
Local Institution
Wulumuqi, Xinjiang, China, 830001
China, Zhejiang
Local Institution
Hangzhou, Zhejiang, China, 310006
Local Institution
Hangzhou, Zhejiang, China, 310023
Local institution
Hangzhou, Zhejiang, China, 310000
Local Institution
Jinghua, Zhejiang, China, 300000
Local Institution
Ningbo, Zhejiang, China, 315010
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided

Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01726439     History of Changes
Other Study ID Numbers: AI463-952
Study First Received: November 6, 2012
Last Updated: June 23, 2014
Health Authority: China: Ministry of Health

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis, Chronic
Hepatitis B, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections

ClinicalTrials.gov processed this record on July 31, 2014